FILO is a Cooperative Group aiming at implementing and carrying out biomedical, epidemiological, clinical, pharmacological and biological research in the field of Chronic Lymphoid Leukemia (CLL), Waldenström's Disease (WM), Acute Myeloblastic Leukemia (AML) and other myeloproliferatives diseases such as Myeloproliferative Syndromes. It also endeavors to pursue educational and / or informative actions intended for medical professionals and patients.
You will find more information about these diseases, their management and their treatment on the SILLC patients website.
Creation and merger
Since 2006, the French Cooperative Group (CLL/WM) has teamed up with the Groupe Ouest-Est des Leucémies et Autres Maladies du Sang (GOELAMS) to form the GCFLLC / MW Intergroup. The "marriage" of these two entities, in November 2015 in Reims, led to the creation of the a new group called FILO: French Innovative Leukemia Organization.
This non-profit association is an institutional group for clinical research in the field of hematological malignancies. The merger makes possible to pool human resources and biological circuits in order to develop clinical research in France while being part of an international strategy.
The FILO association is implementing several approaches to achieve its objectives and progress in the treatment of hematology. Through its work and partnership with various organizations involved in this fight, case management and case studies are of better quality and produce encouraging results.
FILO clinical research activity in France involves 60 centers (University Hospitals (CHU), Cancer Centers (CAC) and private institutions) in 20 to 30 multicenter clinical trials from phase I to III. Several thousand patients are enrolled and treated in clinical trials. FILO brings together French and Belgian specialists interested in the study of these diseases and constantly seeks to establish international contacts to improve mutual knowledge.
FILO is also the promoter of national multicenter clinical trials in the field of hematology: chronic lymphoid leukemia (CLL), Waldenström macroglobulinemia (WM) and acute myeloblastic leukemias (AML). It collaborates with the FIM for the study and management of myelofibrosis and essential thrombocythemia and with the LYSA (fusion of GELA and GOELAMS in 2012) for Hodgkin's disease and non-Hodgkin lymphomas (NHL).
FILO also participates in national or international clinical studies promoted by the industry to pursue progress in the management of these complex diseases.
You will find on this site:
Presentation and operation of the FILO website;
Member information and therapeutic trials of the FILO CLL / MW group;
Member information and therapeutic trials of the FILO AML / other pathologies group;
Contacts and links to other websites devoted to these diseases.
For members of the FILO group, a link allows access via the "member access" tab to the extranet site, which contains all documents to be shared (protocols, meeting dates, meeting reports, slideshows, workgroups…).
Below is the organization of the FILO group and its representatives:
President: Pr Véronique LEBLOND (Paris Pitié Salpetrière FRANCE).
Vice-President: Pr Jean Yves CAHN (Grenoble FRANCE).
Headquarters and Coordination : Tours University Hospital, Hematology and Cellular Therapy, FRANCE
Board of 26 members.
Collections of biological samples (FILOthèque for AML in Cochin Hospital, Paris, PAris; CLL at Caen, France and Tours CRBs France).
Two Scientific Committees (CS) for each hematological pathology:
CS FILO CLL : chaired by Pr. Pierre FEUGIER, Pr. Alain DELMER.
CS FILO AML: chaired by Pr. Christian RECHER.